Alliance Pharma PLC Annual Report and Preliminary Results correction (7825T)
March 29 2021 - 2:13AM
UK Regulatory
TIDMAPH
RNS Number : 7825T
Alliance Pharma PLC
29 March 2021
For immediate release 29 March 2021
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Annual Report and Accounts
and correction to FY2020 Preliminary Results
ANNUAL REPORT AND ACCOUNTS
Alliance Pharma plc (AIM: APH) announces that the Annual Report
and Accounts for the year ended 31 December 2020 are now available
on the Group's website, www.alliancepharmaceuticals.com
Printed copies will be mailed on or before 9 April 2021 to those
shareholders who have opted out of receiving electronic
communications.
Printed copies will also be available from Buchanan and may be
requested by e-mailing alliancepharma@buchanan.uk.com or by
telephoning 020 7466 5000.
CORRECTION TO FY2020 PRELIMINARY RESULTS
Following release of the Group's preliminary results for the
year ended 31 December 2020 on 23 March 2021, an error in the
mathematical calculation of the weighted average number of Ordinary
shares was identified.
The correct weighted average number of Ordinary shares for the
12 months ended 31 December 2020 for the Basic EPS calculation is
531,062,798, and not 521,686,254 as originally stated in the
preliminary results on 23 March 2021. The correct weighted average
number of Ordinary shares for the Diluted EPS calculation is
537,318,838 and not 527,924,294 as originally stated in the
preliminary results announcement on 23 March 2021.
This increase in the number of shares results in a small
reduction to EPS measures which are correctly stated as
follows:
Year ended 31 December 2020 As stated
Correctly on 23
stated March
(p) 2021 (p)
Reported basic earnings per
share 1.51 1.54
----------------------------- ------------ ----------
Reported diluted earnings
per share 1.49 1.52
----------------------------- ------------ ----------
Underlying basic earnings
per share 5.11 5.21
----------------------------- ------------ ----------
Underlying diluted earnings
per share 5.05 5.14
----------------------------- ------------ ----------
The corrected numbers have been reflected in the Group's 2020
Annual Report and Accounts and in the version of the FY2020
preliminary results statement available on Alliance's website.
The detail of the EPS calculation is set out in note 10 of the
Annual Report and Accounts.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah
Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
/ Oliver Steele
Corporate Broking: James Black
Investec Bank plc + 44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group, headquartered in the UK with subsidiaries in Europe, the Far
East and the US and wide international reach through an extensive
network of distributors, generating sales in more than 100
countries.
We hold the marketing rights to around 80 Consumer Healthcare
brands and Prescription Medicines, which are managed on a portfolio
basis according to their growth potential. Promotional investment
is focused primarily on our Consumer healthcare brands, many of
which have significant international or multi-territory reach. Our
Prescription Medicines are generally sold in a more limited number
of local markets, and most require little or no promotional
investment.
Our strategy allows us to deliver good organic growth and to
enhance our growth rate through carefully selected
acquisitions.
For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSPPUUGWUPGUMB
(END) Dow Jones Newswires
March 29, 2021 03:13 ET (07:13 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024